According to the above data, the selective agonists of the GABA-A receptor complex are the drugs of first choice in the drug treatment of insomnia. [22] Once treatment has started, monitoring and ...
Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.
Belsomra has taken a healthy share of the insomnia market from drugs, but the category overall is dominated by generic medicines and has been in decline for some time, although Merck’s drug is ...